ARS Pharmaceuticals, Inc. (SPRY) Free cash flow 2020–2025
ARS Pharmaceuticals, Inc. (SPRY) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$171.2MFY2025 · since FY2020: -$32.1M → -$171.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$171.2M | -1418.5% |
| FY2024 | $13.0M | +121.8% |
| FY2023 | -$59.4M | -47.6% |
| FY2022 | -$40.3M | -128.6% |
| FY2021 | -$17.6M | +45.1% |
| FY2020 | -$32.1M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More SPRY financial trends
SPRY RevenueSPRY Net incomeSPRY Net marginSPRY Gross profitSPRY Gross marginSPRY Operating incomeSPRY Operating marginSPRY Operating cash flowSPRY Capital expendituresSPRY Return on equitySPRY Stock buybacksSPRY Dividends paidSPRY Total assetsSPRY Total liabilitiesSPRY Shareholders’ equitySPRY overview →